The Retrospective Study Of Anlotinib In Second-line And Above Treatment For Advanced Lung Squamous Cell Carcinoma

Objective:To retrospectively analyze the efficacy and side effects of patients using anlotinib who were diagnosed as lung squamous cell carcinoma from the hospital and explore related factors that affect the efficacy of anlotinib.Methods:This study included 45 patients with lung squamous cell carcinoma diagnosed by pathology in our hospital,and collected basic information,and adverse events of selected cases.SPSS 17.0 software was used for statistical analysis of relevant data.Kaplan-Meier method and Log-rank test were used for univariate survival analysis.Cox regression model was used for multivariate analysis to find independent factors affecting its prognosis.P<0.05 indicates a statistical difference.Results:1.A total of 45 patients with advanced lung squamous cell carcinoma were included in this study,and the baseline was basically balanced,including 0 CR,5 PR,23 SD,and 17 PD.The objective response rate was 11.1%,and the disease control rate was 62.2%.2.Survival analysis showed that the patients had a median PFS of 4.5 months and a median OS of 7.2 months.3.Safety: 1 case of grade 3 hand and foot skin reactions,1 case of grade 3hemoptysis,1 case of grade 3 nausea and vomiting,and no adverse reactions of grade 4 or above.4.Univariate analysis showed that the ECOG PS score,brain metastasis,and previous lung radiotherapy were the prognostic factors affecting the treatment of advanced lung squamous cell carcinoma with anlotinib.Multivariate COX regression analysis showed that the ECOG PS score and brain metastasis affected theindependent prognostic factor for the treatment of advanced lung squamous cell carcinoma.Conclusions:1.Anlotinib has a definite effect in the treatment of advanced lung squamous cell carcinoma of the second line and above,and the adverse reactions can be tolerated.2.ECOG PS score,brain metastasis,and previous lung radiotherapy are the prognostic factors that affect the treatment of advanced lung squamous cell carcinoma with anlotinib.ECOG PS score and brain metastasis are independent prognostic factors that affect anlotinib in the treatment of advanced lung squamous cell carcinoma.